Pulmonary & Critical Care Division Newsletter

December 2025

Welcome to the December 2025 edition of our division newsletter. Below you’ll find updates from each department including research highlights, clinical news, social updates, and more.

Fellowship

CHEST 2025 Recognition
Congratulations to Dr. Yolanda Hidalgo Hernandez, whose rapid-fire case report, “Restoring Flow, Relieving Breath: Pulmonary Artery Stenting as a Novel Approach for Malignant Vascular Compression,” received the Top Rapid-Fire Case Report Award at CHEST 2025.
This project was mentored by Dr. Alex Garbarino, and Dr. Hidalgo Hernandez expressed gratitude for his guidance as well as the strong training and support she’s received from our program.


Recent Publications

Congratulations to Dr. Medha Reddy Cherabuddi and Dr. Rana Awdish on their new publication titled “Challenges and Benefits to Adapting the C.L.E.A.R. Conversations Curriculum for Physician–Patient Communication to an Online Format: A Qualitative Interview Study.” Journal of Medical Education and Curricular Development. 2025

This work highlights the evolving landscape of physician–patient communication training and the opportunities - and challenges - of transitioning established curricula into virtual learning environments.

Announcements

Successful Match 2025
We are thrilled to announce that we had another highly successful Match this year.
Thank you to all faculty, fellows, APPs, and staff whose dedication, mentorship,
and effort made this possible. The following fellows will be joining our division in
July 2026:



Pulmonary & Critical Care Medicine (PCCM)



  • Amira Al-Nabolsi (Corewell Health)

  • Shannon Antishin (Henry Ford Hospital – Main)

  • Jawad Bouhamdan (University of Michigan–Ann Arbor)

  • Jonathan Major (Henry Ford Hospital – Main)

  • Niroshan Ranjan (Henry Ford Jackson)

  • Quintin Solano (University of Michigan–Ann Arbor)

  • Marwa Nabil Tarbaghia (Cleveland Clinic)





Critical Care Medicine (CCM)



  • Raya Bani Kenana (IM – Henry Ford Hospital Main)

  • Chandana Cherukupalli (EM – Henry Ford Hospital Main)

  • Michael Derevensky (IM – University of Vermont)

  • Connor Bunch (EM/IM – Henry Ford Hospital)

  • Cassidy Merklen (EM/IM – Henry Ford Hospital)

  • Nosike Obionwu (Nephrology/CCM)

  • Heitor Smiljanic Carrijo (Nephrology/CCM)




Pulmonary Highlights


A Closer Look at Our New Asthma Clinic: An Interview with Dr. Dania Shakaroun

Severe asthma remains a persistent and difficult-to-manage condition in Southeast Michigan, prompting the development of our new Asthma Clinic. We spoke with Dr. Dania Shakaroun, who leads the initiative, to understand its purpose, early impact, and long-term vision.

“The severity of asthma in Southeast Michigan is significant,” Dr. Shakaroun noted. “We saw patients with moderate to severe asthma who remained poorly controlled despite appropriate inhaler therapy. Many of them were strong candidates for advanced testing or biologic therapy, but escalation was often delayed or fragmented.”

The clinic was created to deliver a centralized, comprehensive model of asthma care that integrates phenotype assessment, treatment history, comorbidity evaluation, and barrier mitigation. “In many cases,” she explained, “we’re able to perform same-visit allergy and pulmonary evaluation, determine biologic eligibility, and initiate the escalation strategy without delay.”

Who should be referred? “Our target patients,” she clarified, “are those with uncontrolled asthma—especially if they are requiring frequent steroids, have recurrent exacerbations, or if the conversation has already shifted toward biologic therapy. Those are the referrals we most want to see.” She emphasized early referral rather than waiting for multiple failures or hospitalizations.

Although active for less than a year, early impact has been encouraging. The ability to execute evaluation, testing, and treatment adjustments in a single visit has already led to improved disease stability. Over the coming months, she expects to see measurable reductions in steroid use, emergency visits, and hospitalizations.

Looking forward, Dr. Shakaroun envisions expansion. “In the next six to twelve months, we want to increase awareness and grow our referral volume. Long term, we hope to serve as an education hub and eventually develop asthma-focused research efforts within the division.”

Multidisciplinary collaboration has been central to the clinic’s success. “Working closely with allergy has been transformative,” she explained. “During our Comprehensive Asthma Clinic on K13, the allergy team can scope patients during the same visit to evaluate for nasal polyps and perform allergy testing immediately. That level of on-site coordination dramatically accelerates diagnosis and treatment alignment.”

The second clinical service, the K17 Asthma Clinic, runs every Friday and focuses on advanced asthma management and treatment optimization. The K13 Comprehensive Clinic incorporates allergy collaboration for deeper phenotyping and procedural access.





“If a patient’s asthma isn’t controlled—especially if they’re on frequent steroids or you’re already thinking about biologics—refer them. That’s why we built this clinic.”

Dr. Dania Shakaroun



Challenges remain, particularly around inhaler adherence and payer approval for biologics. “Some patients simply aren’t using inhalers consistently or correctly,” said Dr. Shakaroun. “We’re improving follow-up structure and engaging insurers earlier to prevent care delays.”






Spotlight: Dr. Genva Tatem, New Editor-in-Chief of ATS Scholar

We are proud to highlight Dr. Genva Tatem, who was recently appointed Editor-in-Chief of ATS Scholar. The role has already become one of the most meaningful parts of her career. “It’s been a great opportunity,” she shared, “being able to help people get their educational work out and published and disseminated, and advance their careers has been a highlight of my career thus far.”

Dr. Tatem’s enthusiasm comes not only from the editorial work itself, but from seeing how scholarship can reshape careers. As she explained, guiding authors through the process from submission to publication offers a firsthand look at how impactful educational research can be.

One message she stressed for both fellows and faculty is the value of developing peer-review skills early.


“It’s not something that we normally teach,” she noted, “but it’s a great opportunity to really understand how good research is done and helps you develop your projects even that much more effectively from the very outset.”

She encourages fellows who are interested in learning how peer review actually works—the “behind the curtain” view, as she calls it—to reach out. Reviewing manuscripts under supervision, discussing editorial decisions, and examining what makes a submission strong or weak can all accelerate academic growth. “There are lots of chances to learn how to do it,” she said, “and to understand how getting a publication from submission to actually out in the world really works.”

Dr. Tatem welcomes fellows to connect with her about opportunities to participate in peer review and begin cultivating this essential academic skill.


New Leadership Appointments at West Bloomfield



We are pleased to share recent leadership updates within our division. Dr. Dominik Starosta has been appointed Chief of Medicine at West Bloomfield (WB), a role in which he will oversee medical operations and help drive ongoing quality and performance initiatives across the hospital.


In addition, Dr. Kamelia Albujoq has been named the new Division Chief of Pulmonary & Critical Care at West Bloomfield. Her leadership will be instrumental in guiding critical care processes, supporting our MICU teams, and continuing to advance our standards of care.
Please join us in congratulating Dr. Starosta and Dr. Albujoq on their new roles.

ILD

Highlights


PFF Summit 2025 – Chicago, November 2025

The Henry Ford Interstitial Lung Disease (ILD) team was well represented at this year’s Pulmonary Fibrosis Foundation (PFF) Summit in Chicago. Heather Bachert served on the planning committee and delivered two sessions. Dr. Thavarajah presented two podium talks, including one on the benefits of pulmonary rehabilitation in ILD.

We are also proud to share that the Henry Ford ILD Program has been re-designated as a Pulmonary Fibrosis Foundation Care Center. First designated in 2018, the program has successfully completed re-review and continues to be recognized for excellence in ILD care.

ICU

Announcements


The MICU is currently engaged in a CUSP (Comprehensive Unit-based Safety Program) project focused on evaluating whether our patients can be extubated earlier during their morning spontaneous breathing trial (SBT). This work has been developed collaboratively with nursing, respiratory therapy, our fellows, and APPs.

As part of the new process, the day respiratory therapist (RT) will HALO the fellow or APP in the morning with a list of all patients who are on CPAP. The fellow - along with the APP when applicable - will evaluate each patient and determine whether they may be safely extubated at that time. If there are any questions or concerns, they will reach out directly to the attending for clarification.

The goal of this initiative is to promote earlier extubation when clinically appropriate, reduce time on mechanical ventilation, and support improved recovery trajectories through more timely decision-making during the SBT process.

Please direct any questions to Dr. Swiderek, who extends her thanks for your support of this work.

PH

Ongoing Research

1. Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

The NAIL-IT study is evaluating a targeted strategy to enhance thrombus breakdown by inactivating α2-antiplasmin, a key inhibitor of fibrinolysis. Dr. Scott Kaatz serves as Principal Investigator, with essential involvement from the PERT team. This project aims to advance treatment options for patients with acute intravascular thrombosis by improving clot-lysis efficiency.

2. SPIRARE II Clinical Trial

We are participating in SPIRARE II, a clinical trial evaluating the Vertex™ Pulmonary Embolectomy (PE) System, an FDA-authorized investigational device designed for mechanical removal of pulmonary emboli. Conducted in collaboration with our colleagues in Cardiology and Interventional Radiology, this study is assessing a next-generation approach to PE thrombectomy with the goal of improving efficacy and safety.

Administrative

Highlights

Congratulations to Dr. A. Garbarino for providing the winning caption for last week's image.
Upon presentation of the prize, Dr. Garbarino initially sought to redirect the gift card to the fellows. This decision was subsequently reevaluated when a logistical point was raised: that this action could reward trainees for failing to provide an independent, successful caption. Following this brief discussion, Dr. Garbarino enthusiastically accepted the card.



Tip of the month
You can view the full list of prior articles from the fellows’ Monday Journal Club on hfhpulm site:

Announcements

Starting January 1, there are important updates for our HAP Medicare patients. CVS will no longer be part of the pharmacy network. Preferred pharmacies now include Pharmacy Advantage, Henry Ford outpatient pharmacies, Costco, Walgreens, and Kroger.<
In addition, Ventolin HFA inhalers will be removed from the formulary. Please prescribe albuterol HFA instead and indicate the number of packages needed.<

Amber and her team remain committed to supporting everyone through these transitions.